These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9121269)

  • 21. Co-activator and co-repressor interplay on the human androgen receptor.
    Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
    Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
    [No Abstract]   [Full Text] [Related]  

  • 22. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
    Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.
    Wang Y; Li JQ; Shao C; Shi CH; Liu F; Yang ZY; Qiu JX; Li YM; Fu Q; Zhang W; Xue W; Lei YH; Gao JY; Wang JY; Gao XP; Yuan JL; Bao TY; Zhang YT
    Ir J Med Sci; 2011 Dec; 180(4):865-72. PubMed ID: 21748440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
    Zhou J; Liu B; Geng G; Wu JH
    Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
    Miyamoto H; Yeh S; Wilding G; Chang C
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators.
    Yeh S; Chang HC; Miyamoto H; Takatera H; Rahman M; Kang HY; Thin TH; Lin HK; Chang C
    Keio J Med; 1999 Jun; 48(2):87-92. PubMed ID: 10405524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
    Figg WD; Sartor O; Cooper MR; Thibault A; Bergan RC; Dawson N; Reed E; Myers CE
    Am J Med; 1995 Apr; 98(4):412-4. PubMed ID: 7535978
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T).
    Marugo M; Bernasconi D; Miglietta L; Fazzuoli L; Ravera F; Cassulo S; Giordano G
    J Steroid Biochem Mol Biol; 1992 Jun; 42(5):547-54. PubMed ID: 1616884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
    Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model.
    Ilagan R; Zhang LJ; Pottratz J; Le K; Salas S; Iyer M; Wu L; Gambhir SS; Carey M
    Mol Cancer Ther; 2005 Nov; 4(11):1662-9. PubMed ID: 16275987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
    Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
    J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis for the antiandrogen withdrawal syndrome.
    Miyamoto H; Rahman MM; Chang C
    J Cell Biochem; 2004 Jan; 91(1):3-12. PubMed ID: 14689576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Walsh PC
    J Urol; 1996 May; 155(5):1705. PubMed ID: 8627865
    [No Abstract]   [Full Text] [Related]  

  • 37. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Small EJ
    J Urol; 1996 May; 155(5):1704-5. PubMed ID: 8627864
    [No Abstract]   [Full Text] [Related]  

  • 38. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.
    Mitchell SH; Zhu W; Young CY
    Cancer Res; 1999 Dec; 59(23):5892-5. PubMed ID: 10606230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
    Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antiandrogen withdrawal syndrome.
    Wirth MP; Froschermaier SE
    Urol Res; 1997; 25 Suppl 2():S67-71. PubMed ID: 9144890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.